Tyrosine News and Research RSS Feed - Tyrosine News and Research

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics. [More]
Microtubules affect mechanics of beating heart, study finds

Microtubules affect mechanics of beating heart, study finds

On top of the meaning and mystery that humans heap on the heart, it is first and foremost, a muscle. And one that beats about once a second for a person's entire life, with no rest. Given its vital importance, it's ironic researchers have only recently made direct observations of its subcellular parts in motion. [More]
BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers. [More]
Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia. [More]
Frontline nilotinib supported for newly diagnosed CP-CML

Frontline nilotinib supported for newly diagnosed CP-CML

Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis. [More]
Pre-TKI cytokine profiling predicts CP-CML outcome

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests. [More]
Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities can be used to create two prognostic groups of patients with chronic myeloid leukaemia, suggests research published in Blood. [More]
Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies. [More]
M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication. [More]
Metabolic pathway activates cell signaling protein to promote breast cancer metastasis

Metabolic pathway activates cell signaling protein to promote breast cancer metastasis

A metabolic pathway that is up-regulated in certain breast cancers promotes the disease's progression by activating a cell signaling protein called Arf6, according to a paper published in the Journal of Cell Biology. [More]
Versatile automated microplate sample screening applications: an interview with Tobias Pusterla

Versatile automated microplate sample screening applications: an interview with Tobias Pusterla

Microplate readers are divided into single-mode and multi-mode readers. A single mode reader is mainly a reader dedicated to the detection of absorbance, luminescence or fluorescence. [More]
High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. [More]
MU researchers use MRI to study effects of Phenylketonuria

MU researchers use MRI to study effects of Phenylketonuria

All children are screened for a host of conditions at birth, such as Phenylketonuria (PKU), a genetic disorder that is passed by mutated genes from both parents to their offspring. PKU is rare, only affecting one in every 10,000 children in the U.S.; therefore, it is seldom studied. [More]
Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease. [More]
MRX-2843 treatment improves survival of acute myeloid leukemia patients

MRX-2843 treatment improves survival of acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors. [More]
Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate. [More]
Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest. [More]
Real-life data show feasibility of imatinib discontinuation in CML

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA). [More]
Advertisement
Advertisement